Vitamin D signaling in a mouse allergic sensitization model by Lucas, Renata et al.
News and Views
Vitamin D signaling in a mouse
allergic sensitization model
Renata Lucas1, Johanna Mihály2, Janine Gericke2, Dániel Törőcsik1, and Ralph Rühl2,3
1 Department of Dermatology, University of Debrecen, Hungary
2 Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary
3 Paprika Bioanalytics BT, Debrecen, Hungary
Abstract: Vitamin D mediated signalling in the skin is discussed controversially for its beneficial or detrimental influence. In this study we
examined various factors involved in Vitamin D-mediated signalling in a mouse model for allergic dermatitis with systemic (OVA IP) and
systemic plus topical allergic sensitization (OVA IP + EC). We found that the major enzyme responsible for 1,25-Vitamin D3 synthesis, the
1-hydoxylase CYP27B1 (3,6-fold for OVA IP and 2,7-fold for OVA IP + EC), the vitamin D receptor (not altered) and the sensitive Vitamin D-
mediated signalling target gene CYP24A1 (65-fold in OVA IP and 726-fold in OVA IP + EC) are upregulated after systemic and systemic plus
topical allergic sensitization (OVA IP + EC). In consequence, active Vitamin D-mediated signalling is involved in systemic as well as
systemic/topical allergic sensitization in mouse skin.
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Introduction
Vitamin D has been involved in maintenance of normal
epidermal barrier, skin homeostasis and a disturbed
vitaminD-mediated signaling is associated with inflamma-
tory skin diseases such as atopic dermatitis (AD) [1]. Till
now however the available studies are not coherent about
the involvement of vitaminD-signaling pathways in allergic
diseases [2]. In various studies, reduced serum levels of
25-hydroxy vitamin D3 (25VD3) were observed in patients
with AD [3, 4], but the status of vitamin D-mediated
signaling is not well studied in skin of AD patients.
The skin is a main target organ of vitamin D synthesis in
which biologically active 1,25-dihydroxy-vitamin D3
(1,25VD3) is metabolized starting from 7-dihydrocholes-
terol, which after exposure to UV is phototransformed to
VD3, a substrate for 25-hydoxylation (CYP27A1 and
CYP2R1), 1-hydroxylation (CYP27B1) to the active vitamin
D metabolite 1,25VD3 [5], which is the potent endogenous
activatorof thevitaminDreceptor (VDR).This active ligand
can further be metabolized and thereby inactivated by
the VDR-target gene, the 24-hydroxylase (CYP24A1) [5].
A better understanding of the status of cutaneous vitamin
D-mediated pathway in AD-skin is crucial for targeted
therapy using systemic or topical treatment strategies with
vitamin D analogues.
Topical and systemic ovalbumin (OVA)-sensitized
mice are widely used for analysis of pathogenesis and
background of allergic diseases. In our experiments, we
sensitized mice systemic or systemic plus topical using
OVA (Figure 1A). Later we examined via qRT-PCR analysis
the expression levels of the nuclear hormone receptors
RXR, VDR and various previously mentioned vitamin D
synthesizing enzymes in skin samples after allergic
sensitization.
Materials and methods
Animal experiments; 8–10 weeks old female BALB/c mice
(n = 6, per group) were treated intraperitoneally (i.p.) with
phosphate-buffered saline (PBS, Figure 1A a) or with
10μgOVA(Figure 1Ab)adsorbed to 1.5mgAl(OH)3ondays
47, 60, and 67 [6]. A third group of mice (female BALB/c
mice (n = 6, per group) were treated intraperitoneally (i.p.)
with 10 μg OVA adsorbed to 1.5mg Al(OH)3 on days 1, 14,
and 21 of experiment, following epicutaneous (e.p./topical)
application of 100 μg OVA absorbed to 1.5 mg Al(OH)3 in
100 μl PBS (weekly dose) [6]. Animal experiments were
approved by the Committee of Animal research of the
University of Debrecen, Hungary (Approval number:
25/2006 DEMAB). Shaved dorsal skin was treated with
25μl OVA solution on every other day of a one-week period.
There were three periods of topical OVA treatment with
two-week intervals. Mice were always shaved the day
before the first and the third topical application of OVA.
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Figure 1. A. Schematic model of the allergic sensitization of 8–10 weeks old female BALB/c mice (n = 6, per group) by repetitive systemic and
topical application of OVA. B. Hematoxylin and Eosin staining of five μm skin sections obtained from treated dorsal skin sites. Images were taken
at !10 magnification (scale bar = 50 μm). Figures are reproduced from [6] and the materials and methods used are described in this previous
study. C. Induced mRNA expression of genes involved in vitamin D metabolism in i.p. OVA-treated mice with or without e.c. OVA exposure. Heat
map shows fold change of gene expression in mice skin treated systemically with OVA followed by or not topical OVA exposure compared to PBS
control group. Color codes: dark red – significantly up-regulated; light red – non-significantly up-regulated; grey – not altered (±20%); light blue –
non-significantly down-regulated; dark blue – significantly down-regulated.
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Three days after the last treatment (day 70) mice were
sacrificed; skin and serum samples were collected and kept
at –80 "C until analyses. This mouse study was already
examined for retinoid signaling [6] and topical TSLP
regulation [7].
PCR analysis; was performed like previously described
[6] including statistical evaluation using ANOVA and
differences were considered significant at p < 0.05.
RNA preparation and reverse transcription; Total RNA
was isolated fromfrozen skinusingTri# reagent (Molecular
Research Center Inc., Cincinnati, OH) following the
manufacturer’s instructions. 750 ng of total RNA were
reverse transcribed into cDNA in a 30 μl reaction using
the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Budapest, H) according to the manufac-
turer’s protocol.
Analysis of mRNA expression; mRNA expression in skin
was determined by means of quantitative real time-PCR
(qRT-PCR) and TaqMan# Low Density Arrays (TLDA) on
an ABI Prism 7900. qRT-PCR measurements were
performed in triplicate using pre-designed TaqMan#Gene
Expression Assays and reagents; TaqMan# Low Density
Array cards were used for duplicate determinations using
TaqMan# Gene Expression Master Mix (all Applied
Biosystems Applera Hungary, Budapest, H). Relative
quantification of mRNA expression was achieved using
the comparative CT method and values were normalized
to cyclophilin A mRNA. Gene expression values below
detection limit were assumed to be zero for the purpose of
statistical analysis.
Results
Histological examination was reproduced from a previous
study [6]. Sensitization with OVA induced mild focal
hyperplasia with a ca. two-fold (OVA i.p. vs. PBS i.p.) or
ca. three-fold (OVA i.p. + e.c. vs. PBS i.p. vs. OVA i.p.)
increase in epidermal thickness, respectively (Figure 1B).
The histological analysis further revealed scaly skin
comparable to human atopic dermatitis phenotype in both
OVA-sensitized groups (Figure 1B).
The expressions of RXRα, VDR-synthesizing enzymes
and a VDR-target gene were mainly increased in systemic
and systemic and topical OVA-sensitized mice compared
to control group shown as a heat map in Figure 1C and as
supplemental table 1. The expression of RXRα and the
mitochondrial 25-hydroxylase CYP27A1 were increased
only in systemic plus topical OVA-sensitized animals
(significantly 1.6-fold for RXR and with tendency 1.4-fold
for CYP27A1), while its expression was slightly reduced by
systemic application of OVA (with tendency 0.7-fold for
RXR and significantly 0.5-fold for CYP27A1, Figure 1B).
The expression of the microsomal 25-hydroxylase CYP2R1
and the 1-hydroxylaseCYP27B1were increased both in sys-
temic (with tendency 3.3-fold for CYP2R1 and significantly
2.6-fold for CYP27B1) and systemic plus topical sensitized
mice (with tendency 1.5-fold for CYP2R1 and significantly
2.7-fold for CYP27B1) (Figure 1C and supplemental
table 1). These results indicate upregulation of 1,25VD3-
synthesis in the skin of systemic as well as systemic plus
topical sensitized mice. In addition, the expression of the
VDR-target gene 24-hydroxylase [5] was also upregulated
both in the skin of systemic (significantly 65-fold) and sys-
temic plus topical allergic sensitized animals (significantly
726-fold).
Discussion
In summary, increased expression of RXRα, the key
1,25VD3-synthesizing enzyme (CYP27B1) and the most
sensitive vitaminD-target geneCYP24A1display increased
VDR-mediated signaling in the skin of systemic as well as
systemic plus topical sensitized mice. In controversy,
CYP24A1 also indicates increased catabolism of the active
endogenous ligand 1,25VD3 to auto-downregulate VDR-
mediated signalling via reduction of available ligand
concentrations [5]. This detected increased vitamin D-
mediated signaling may favor pro-allergic conditions pre-
sent in skinof sensitizedmice [1].These results confirmalso
our and others data where increased vitamin D-mediated
signaling is present in affected and non-affected skin of
AD-patients (Weise et al. personal communication/submit-
ted). We believe, that in opposite to the major current
believe of reduced vitamin D levels in serum because of
reduced availability of vitamin D in AD-patients [3, 4],
instead increased local vitamin D-mediated signaling at
the site of inflammation is present and reduced vitamin D
levels are thereby present in AD-patients as a consequence
of the systemic and/or topical allergic sensitization, compa-
rable to the situation of vitamin A [8].
We suggest that strategies using systemic vitamin D
supplementation to AD-patients with a systemic and/or
topical allergic sensitization, like suggested by others [9],
are apotential dangerous strategy circumventing important
defense strategies of the human organism to prevent
increased pro-inflammatory and pro-allergic vitamin D-
mediated signaling inAD-patients.Wepropose that instead
topical treatment strategies antagonizing VDR-mediated
signaling might be a useful strategy for AD therapy with a
topical allergic sensitization background.
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ESM 1. Systemic and topical OVA sensitization results in
altered VDR-mediated signalling indicated by the Vitamin
D receptor (VDR), the retinoid X receptor alpha (RXRα),
the vitamin D metabolizing enzymes; CYP27A1, CYP2R1,
CYP27B1 and CYP24A1. The CYP24A1 is also the most
sensitive marker gene for VDR-mediated signalling. Fold
change data are expressed as mean ± SEM (n = 6) and
were determined in skin specimen of sensitized mice. Sta-
tistical significance (p) was tested using one-way ANOVA
followed by Tukey’s multiple comparison test." – indicates
statistical significance with p < 0.05. e.c., epicutaneous;
i.p., intraperitoneal; OVA, ovalbumin (Table E1).
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